OCGN
Closed
Ocugen Inc
0.9241
-0.0463 (-4.77%)
Last Update: 01 Jul 2025 23:14:00
Yesterday: 0.9704
Day's Range: 0.91 - 0.9601
Send
sign up or login to leave a comment!
When Written:
0.7835
Ocugen Inc is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing gene therapies to cure blindness diseases. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Ocugen's lead product candidate is a gene therapy for the treatment of retinitis pigmentosa, a rare genetic disorder that causes progressive vision loss. The company is also developing gene therapies for other ocular diseases, including dry eye disease and diabetic macular edema. Ocugen has partnerships with several academic institutions and industry leaders in the field of ophthalmology. The company's mission is to provide innovative treatments to patients with rare and underserved eye diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
0.7835
Ocugen Inc is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccines for infectious diseases. The company is headquartered in Malvern, Pennsylvania, and was founded in 2013. Ocugen's lead product candidate is OCU400, a gene therapy for the treatment of inherited retinal diseases, and the company is also developing a COVID-19 vaccine candidate in partnership with Bharat Biotech. Ocugen's mission is to develop and commercialize transformative therapies to cure blindness and provide protection against infectious diseases. The company is publicly traded on the NASDAQ exchange under the ticker symbol OCGN.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








